On September 2–3, Henlius (2696.HK) will be honoured to attend the Citi's 2025 Biopharma Back to School Summit in Boston, MA. Hosted by Citi, a leading global financial institution, the summit is an important platform that focuses on biopharmaceutical innovation and industry trends while facilitating in-depth engagement between companies and the capital markets. With formats including high-level fireside chats and one-on-one meetings, the event provides valuable opportunities for innovative biopharma companies to engage with global investors and showcase their progress.

As a leading China-based biopharmaceutical company with an accelerating global footprint, Henlius will leverage this platform to highlight its accelerated advancement toward the “2.0 era” of innovation-driven globalization, along with its latest achievements in differentiated innovation and global commercialization. By engaging with global investors and industry stakeholders, the company will further convey the strategic value of “innovation-driven globalization,” continuously building itself into a globally competitive and innovative biopharma, and creating greater impact for China-originated biologics on the international stage.

Henlius has always adhered to its patient-centric mission, dedicated to providing high-quality, affordable treatment options to patients worldwide. Moving forward, the company will continue to accelerate the global rollout of its innovative therapies, contributing more of China's strength to the advancement of human health.

Event Preview

Citi’s 2025 Biopharma Back to School Summit

Time: September 2, 2025, 1:45 PM – 2:25 PM ET

Session: Fireside Chat